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Abstract Introduction Concurrent chemoradiation is the standard of care in inoperable locally
advanced squamous cell head and neck cancers. The most widely accepted schedule of
concomitant cisplatin is 100mg/m2 given on a 3 weekly basis but the optimal regime is
unknown.
Objective The objective of this study is to assess the tolerability, compliance, and
clinical outcomes of weekly cisplatin (40mg/m2).
Methods During the period of January 2007–December 2009, we analyzed retrospec-
tively 122 patients with histologically proven squamous cell carcinoma of head and neck
(nasopharynx, oropharynx, larynx, hypopharynx, and oral cavity) treated with definitive
chemoradiation. All patients received 63 Gy in 30 daily fractions with concomitant
weekly cisplatin 40mg/m2. We assessed treatment toxicities and patient compliance.
We estimated overall survival using the Kaplan-Meier method.
Results Sixty-eight percent of patients managed to complete all six cycles of chemother-
apy while 87% of patients completed at least 5 cycles of weekly cisplatin. Incidence of grade
3/4 toxicity was as follows:mucositis 33%, dermatitis 41%, dysphagia 15%,mouth/neck pain
17%, neutropenia 2%, and renal impairment 3%. 53% patients required at least one hospital
admission for symptom control. The 5-year overall survival rate was 60%.
Conclusion Concurrent chemoradiotherapy using weekly cisplatin at 40mg/m2 per
week is an effective, well tolerated regimen allowing most patients to receive at least 5
cycles of chemotherapy. However, a phase III randomized control trial comparing the
standard dose of 100mg/m2 cisplatin tri-weekly with a weekly regimen is needed to
establish the long term clinical outcome.
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Introduction with Objectives
Head and neck cancers (HNC) are heterogeneous group of
cancers and as a whole, they are the fifth most common
cancer worldwide with an estimated annual global incidence
of over half a million.1 Treatment approaches vary depending
upon the location of the tumor, staging, and individual
patient’s characteristics. Optimal treatment for locally
advanced HNC remains a challenge and concurrent chemo-
radiotherapy is the established standard of care for patients
with inoperable disease or patients in whom surgery would
be associated with unacceptable morbidity. The main treat-
mentmodality is external beam radiotherapywith or without
chemotherapy. The most commonly used chemotherapeutic
agent is cisplatin. The additional absolute benefit in overall
survival of adding platinum based chemotherapy has been
best estimated as 6.5% at 5 years when compared with
radiotherapy alone.2 The optimal regimen of cisplatin is yet
to be defined. However, the most widely used concurrent
chemoradiation schedule uses high-dose bolus cisplatin
100mg/m2 every three weeks, in combination with standard
radiotherapy.3–6 The addition of concurrent chemotherapy to
high dose external beam radiotherapy is often associated
with increased toxicity and affects patient compliance with
treatment completion. It also often involves an in-patient stay
in the hospital for chemotherapy, which could potentially
result in treatment delays.
Weekly cisplatin 40mg/m2 has been the standard regimen
for concurrent chemoradiotherapy for HNC at our institution.
This retrospective study attempts to review the experience of
external beam radiotherapy (63 Gy in 30 daily fractions)
with concurrent weekly cisplatin 40 mg/m2. The objective of
this retrospective study was to review the efficacy of this
regime, evaluating the treatment response, patient compli-
ance, toxicities, and outcomes of the treatment. We have also
investigated the prognostic factors affecting the clinical
outcome.
Methods
Patient Population
Patients with head and neck cancers who underwent definitive
primary chemoradiotherapy over a period of three years (Janu-
ary2007–December2009)were identified fromourdepartment
database.We only included patientswith a histologically proven
squamous cell carcinoma of the nasopharynx (n ¼ 7), orophar-
ynx (n ¼ 74), larynx (n ¼ 12), hypopharynx (n ¼ 16) and oral
cavity (n ¼ 13). We excluded patients with primary tumors of
salivary glands, nasal cavity, paranasal sinuses, and unknown
primaries or patient with non-squamous cell carcinomas. We
alsoexcluded fromthestudypatients treatedadjuvantlyor those
who received chemotherapyother thanweeklycisplatin. In total,
there were 16 patients who received chemotherapy other than
weekly cisplatin. Out of these 16 patients, 12 (oropharynx,
n ¼ 5; hypopharynx, n ¼ 3; oral cavity, n ¼ 3, larynx, n ¼ 1)
received treatment with mitomycin C. Of these 12 patients, ten
were with stage IV. Seven patients died. The median survival of
this cohort was 58 months. One patient, a 57-year-old man
with T2N2 oropharyngeal carcinoma, received cetuximab. He
remained alive after five years of follow-up. The remaining three
patients received carboplatin. Of these three patients, two
presented with stage IV disease with mixed histology of squa-
mous and small cell carcinoma. Both patients died after 4 and 6
months of diagnosis. Third patient with stage III nasopharyngeal
carcinoma was lost to follow-up.
The clinical characteristics of the patients are summarized
in►Table 1. Themedian agewas 57 years (range: 35–79). The
majority of the patients had locally advanced disease (72%
patients with stage IVa disease followed by 22% patients with
stage III disease, ►Table 2). A significant number of patients
(82%) had WHO performance status, 0 or 1. Seventy-nine
patients were smokers or past smokers which represented
65% of the entire group.
Pre-treatment Evaluation
All patients underwent clinical evaluations by the otolaryngo-
logic-surgical team. Pre-treatment investigations included
clinical history and examination, biopsies, imaging (CT  MRI
and/or CT/PET scan), fitness evaluation with WHO perfor-
mance status, and ACE-27 (Adult comorbidity evaluation).7 A
multidisciplinary team comprising of otolaryngologists, clini-
cal oncologists, radiologists, pathologist, dental and plastic
surgeons, clinical nurse specialists, dieticians, and speech and
language therapists met and discussed all patients. The treat-
ment decisions were tailored individually based on clinical
staging, comorbidities, long term functional outcome, and
patient’s choice.
Chemotherapy
We administered weekly intravenous cisplatin in outpatient
day case settings with a dose of 40 mg/m2. We capped the
maximum dose at 70 mg. Patients received a pre- and post-
hydration of 1000 mL of sodium chloride 0.9%. Ten mmol of
magnesium sulfate and 20 mmol of potassium chloride were
added in thepost-hydration saline. Standardprophylactic anti-
emetic protocol was a combination of 5-hydroxytryptamine-3
(5HT3) – antagonists (ondansetron) and dexamethasone.
Radiotherapy Schedule
All patients were treated in a supine position, immobilized
with a customized 5-point beam directed shell. The target
volume definitionwas performed using Oncentra MasterPlan
(Nucletron B.V. Veenedaal, Netherlands) Treatment Planning
System, and the radiation treatment was delivered using step
and shoot intensity modulated radiotherapy (IMRT). All
patients received 63 Gy in 30 daily fractions over six weeks
to the primary tumor site and involved neck nodes. This was
just post-transitional period of switching from 3D conformal
radiotherapy to IMRT for head and neck cancers in our
department so the dose was kept at 63 Gy. However, later
the dose was increased to 65 Gy in 30 fractions, which is our
standard regime now. The uninvolved contralateral neck
nodes that carried an occult metastatic risk greater than
15% received a prophylactic dose of 54 Gy in 30 fractions.
Radiotherapy was delivered with 6-MV photons using linear
accelerators.
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Toxicity Evaluation
We assessed all patients on treatment on a weekly basis in a
review clinic comprising clinical oncologists/specialist regis-
trars, clinical nurse specialists, dietician, speech and language
therapists, and a dental hygienist. We assessed and graded
the treatment toxicities according to the radiation therapy
oncology group (RTOG) and common toxicity criteria (CTCAE)
guidelines.7 We recorded performance status, mucosal reac-
tion, skin reaction, full blood count, urea and electrolytes, and
liver function tests. Patients were considered unfit for che-
motherapy in the case of deterioration of performance status,
deterioration of kidney function (GFR < 50mL/min), or blood
count (absolute neutrophil count < 1.5 and platelets < 100).
For patients who we found to be unfit for a cycle of chemo-
therapy we omitted that particular cycle altogether. No dose
reductions were planned.
Outcome Evaluation
Six weeks after completion of treatment, all patients were
assessed in a joint Head and Neck clinic with the otolaryn-
gology surgical team.We clinically assessed response (clinical
examination followed by laryngoscopywith fiber optic laryn-
goscope). Subsequent follow-up visits were scheduled on
three monthly basis for the first year, a 3 to 6 monthly basis
for the second year and a 6-monthly thereafter for a total
period of five years. Radiological imaging (CT or PET/CT) and
biopsies were performed if patients were found to have any
suspicion of recurrence.
Data Collection and Statistical Analysis
Wecollected the data retrospectively and analyzed the results
using SPSSversion 21. Overall survival (OS)was defined as the
time between the dates of tissue diagnosis to the dates of
death/last seen in clinic. Kaplan-Meier estimates were per-
formed to calculate the OS. The compliance of the patients to
chemotherapy treatments were measured in terms of num-
bers of cycles completed. We reviewed hospital admission
rates during chemoradiation treatment and evaluated factors
that resulted in poor treatment compliance. Univariate anal-
ysis with log rank test was performed to study different
factors correlating to survival and a p < 0.05 was considered
statistically significant.
Table 1 Summary of the patients and their disease characteristics
n %
Total number of patients 122 –
Male/Female 97/25 80/20
Median age (years with range) 57 (35 -79) –
Disease location
Nasopharynx 7 6
Oropharynx 74 61
Larynx 12 10
Hypopharynx 16 13
Oral cavity 13 11
Stage
I 1 1
II 6 5
III 27 22
IV 88 72
WHO performance status
0 70 57
1 30 25
2 19 16
3 3 3
ACE-27
0 90 74
1 18 15
2 10 8
3 4 3
Number of weekly cisplatin chemotherapy cycles completed
6 83 68
5 23 19
4 6 5
3 7 6
2 3 3
Treatment outcome
Response assessable 120 98
CR 92 75
RD (clinically suspicious) 28 23
Salvage surgery 18 15
Pathological CR 11 61
(of 18
patients)
Confirmed RD 7 39
(of 18
patients)
Local recurrences (out of 120 evaluable patients)
No 97 81
Yes 23 19
Distant metastases
(Continued)
Table 1 (Continued)
n %
No 108 90
Yes 12 10
Survival (of total 122 patients)
Alive 73 60
Dead 49 40
Abbreviations: n, total number of patients; ACE-27, Adult Comorbidity
Evaluation-27 as per RTOG guidelines7; CR, complete response; RD,
residual disease.
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Results
Clinical Outcome: Treatment Compliance and Acute
Toxicities
Of 122 total patients, all but two patients completed radiothera-
py. Of these two patients, one patient developed an acute
cerebrovascular event while on treatment and the second
patient required a prolonged hospital admission due to pneu-
monia. Two thirds (68%) of patients managed to complete all six
cycles of weekly cisplatin chemotherapy as shown in ►Table 1.
Overall, 87% of patientsmanaged to receive at least 5 cycles, that
is, a cumulative dose of 200 mg/m2. The remaining 13% of
patients received 2–4 cycles of weekly cisplatin. The incidence
of grade 3 or 4 toxicities was as follows: mucositis (33%),
dermatitis (41%), dysphagia (15%), mouth/neck pain (17%),
neutropenia (2%), and renal impairment (3%). These patients
and details of their toxicities are outlined in ►Table 3. Forty-
seven percent of patients did not require hospital admission
during the course of treatment. Forty percent of patients
required one hospital admission for the management of their
acute toxicities. The remaining 13% of patients requiredmultiple
hospital admissions (Range 2–4).
Clinical Outcome: Response to the Treatment
Response was assessable in 120 patients. Ninety-two patients
(75%) achieved a clinical complete response. Therewas a clinical
suspicion of residual disease in twenty-eight patients (23%) and,
in this group, 18 patients were deemed fit for salvage surgery
(surgery on primary site and neck dissection in 8 patients and
neck dissection alone in 10 patients). Eleven patients had
complete pathological response following surgery and, in the
remaining seven patients, residual disease was confirmed.
Survival
Seventy-three (60%) patients were alive at the time of analysis.
Thirty-one patients (26%) were found to have recurrent disease
and out of these 31 patients, 19 had developed loco-regional
Table 2 Tumor, node, and metastases (TNM) staging and T stage of each subsite (n ¼ 122)
N0 N1 N2a N2b N2c N3
T1 1 4 3 6 1 1
T2 5 9 5 8 4 1
T3 10 6 2 6 6 2
T4 9 7 8 9 9 0
T stage Nasopharynx Oropharynx Larynx Hypopharynx Oral cavity
T1 0 15 0 1 0
T2 4 18 2 5 3
T3 1 18 7 4 2
T4 2 23 3 6 8
Table 3 Summary of toxicities
Toxicity n %
Mucositis
Grade 1/2 82 67
Grade 3 38 31
Grade 4 2 2
Dermatitis
Grade 1/2 72 59
Grade 3 46 38
Grade 4 4 3
Dysphagia
Grade 1/2 104 85
Grade 3 17 14
Grade 4 1 1
Mouth/neck pain
Grade 1/2 71 58
Grade 3 18 14
Grade 4 3 3
Neutropenia
Grade 1/2 26 21
Grade 3 1 1
Grade 4 1 1
Renal impairment 3 3
Number of times of hospital admissions
None 57 47
Once 49 40
Twice 7 6
Thrice 6 5
Four times 2 2
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recurrence, 8 patients haddistantmetastases, and4patients had
developed both local recurrence and distant metastases. Overall
and progression free survival rates are shown in►Figs. 1 and 2,
respectively.
The authors also investigated the prognostic factors that
affected the survival of patients in this study. We found that
the WHO performance status (p < 0.001), stage of disease
(p < 0.02), and tumor subsite (nasopharynx being the most
favorable and oral cavity disease with worst prognosis,
p < 0.02, ►Figs. 3 and 4) impacted on survival. However,
gender (p < 0.7), age (p < 0.55), and number of chemothera-
py cycles completed (p < 0.11) had no statistically significant
impact on survival outcome.
Discussion
Definitive concurrent chemoradiotherapy is considered stan-
dard of care for inoperable locoregionally advanced head and
neck squamous cell carcinomas. Cisplatin is the most com-
mon chemotherapeutic agent used in combination with
radiotherapy. The underlyingmechanism of cisplatin induced
radiosensitization include inhibition of the repair of poten-
tially lethal damage and sublethal damage, its ability to form
DNA adducts and cell cycle arrest in G2 phase.8 The optimal
regimen of concurrent cisplatin chemotherapy remains un-
defined, although the most robust evidence is the use of
100mg/m2 cisplatin on a 3-weekly basis. However, this high
dose cisplatin is associated with significant acute and late
toxicities and the completion rate of the regime remains a
challenge.3,9–12 Due to significant toxicities and poor compli-
ance, there has been a trend toward the use of low dose
Fig. 1 Overall survival of all patients in the study with mean survival of
59 months (95% CI 53 - 64), with 73 patients alive and 49 censored cases.
Fig. 2 Progression-free survival at 5 years (74%), mean progression
free survival of 66 months (95% CI 60–71).
Fig. 3 Subgroup analysis of overall survival by different tumor sites.
Fig. 4 Subgroup analysis of progression free survival by tumor
subsites.
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weekly cisplatin concurrentlywith radiotherapy. There are no
randomized trials to support to the use of low dose weekly
cisplatin to date; published studies are limited to early phase
studies and some small retrospective studies. There are
several published studies with alternative cisplatin regimens
such as 5–7mg/m2/day, 5 days aweek during a 7 week course
of fractionated radiotherapy,13–15 5 doses of 20 mg/m2 for 5
consecutive days,16 or 20mg/m2 on 5 days of weeks 1 and 517
during weeks 1, 4, and 7 of radiotherapy. Similarly, some
studies evaluate the role of weekly cisplatin with the dose
ranging from 30–60 mg/m2 for 6–7 weeks.18–24
In a prospective phase II trial by Sharma et al, weekly
cisplatin 40 mg/m2 for 7 doses chemoradiotherapy (n ¼ 77;
primary sites of oropharynx and nasopharynx) was compared
against radical radiotherapy alone. Complete response was
observed in 80.5% patients in the chemoradiotherapy group
against 67.1% in the radiotherapy alone group (p ¼ 0.04)
however, this benefit was associated with frequent treatment
interruptions (28.9% versus 9.3%; p ¼ 0.003) and hospitalisa-
tion (40.8% versus 20%). The incidence of grade III and IV acute
toxicity was 40% in the chemoradiotherapy group versus 20%
in the radiotherapy alone group (p ¼ 0.015).19
Uygun et al studied two different regimes of cisplatin in a
retrospective analysis. They reviewed weekly 40 mg/m2
(n ¼ 20) and 3-weekly regimen (n ¼ 30) of cisplatin in two
different population groups and there was a statistically simi-
lar response rate and a similar adverse event profile.25 How-
ever, in a retrospective study, Geeta et al reached a different
conclusion: 3-weekly cisplatin was less toxic than a weekly
regime 40 mg/m2, however, the number of patients in this
group was small (n ¼ 32).26 In another indirect retrospective
comparison, Ho et al compared weekly cisplatin 33–40mg/m2
(n ¼ 24)with 3-weekly cisplatin 80–100mg/m2 (n ¼ 27)with
concurrent radical radiotherapy. More patients received a
higher cumulative dose of at least 240 mg/m2 in the weekly
arm as comparedwith the 3-weekly cisplatin (p ¼ 0.04). None
of the patients in 3-weekly arm were able to receive the full
three cycles 100 mg/m2 (maximum cumulative dose of 200
mg/m2). Similarly, more delays (41% versus 29%) and omission
of chemotherapy (17.4% versus 5.6%) occurred in the 3-weekly
compared with the weekly regime, however, toxicity, radio-
therapy overall treatment time and delays were similar
between the two groups.27
In one of the largest studies documenting single-center
experience of weekly cisplatin 30mg/m2 concurrently with
radiotherapy (n ¼ 264), Gupta et al found that with the regimen
of 70 Gy given in 7weeks, themedian number of chemotherapy
cycles was six (range 1–7). Two thirds (65%) of the patients
received  85% of the planned cisplatin dose. The incidence of
acute grade  3 toxicities of mucositis and dermatitis was
present in 29% and 35% of patients, respectively. With a mean
follow-up of 19 months, 5-year disease-free survival was 43%.21
In a recent phase II trial of comparison of weekly (40mg/m2
for seven weeks) versus triweekly (100mg/m2 three doses on
a 3-weekly basis) in patients with locally advanced nasopha-
ryngeal carcinoma (n ¼ 109), weekly cisplatinwas associated
with improved quality of life without compromising the
efficacy. The toxicity profile was similar in both treatment
arms.28 In a recent study by Rivelli et al, the authors have
extensively reviewed the incidence of late toxicities in head
and neck cancer patients treatedwith cisplatin based chemo-
radiation. Dysphagia (25%), xerostomia (40% with IMRT),
hypothyroidism (42%), ototoxicity (27%), and osteoradionec-
rosis (4%) were the most frequently reported late toxicities.
Old age, advanced T stage, larynx/hypopharynx primary, and
neck dissection after chemoradiotherapy were found to be
predictive of late toxities.29
This current study is one of the largest from a European
single center. Our findings support those by Gupta et al, the
largest published single institutional study. Our study
showed similar chemotherapy compliance with better out-
comes. According to our experience, weekly cisplatin is easier
to manage than 3-weekly cisplatin because of closer moni-
toring and its increased flexibility allows for easier dose
adjustment or omission in response to patient morbidity.
Homma et al reached the same conclusion in their study of 53
patients.12 In our study, 6 patients were with stage I/II, which
may explain good survival.
We recognize the limitations of this study. First this is a
retrospective study of patients with squamous cell carcino-
mas of five primary sites of the same region. Second human
papilloma virus (HPV) status was not available for the
patients with oropharyngeal disease as it was not routine
practice in our institution at that time. Third, the chemother-
apy dose was capped at a maximum of 70mg which poten-
tially may have resulted in under dosage of some patients
with increased body habitus. However, this capping of
cisplatin dose may explain relatively less grade  3 toxicities
in our study compared with other studies with weekly
cisplatin, as discussed above.
Conclusion
In conclusion, our study demonstrated weekly (40mg/m2)
cisplatin given concurrently with radiotherapy to a total dose
of 63 Gy in 30 daily fractions over a period of sixweeks can be
safely administered with acceptable toxicity and without
compromising efficacy. However, a phase III randomized
control trial comparing the standard dose of 100mg/m2
cisplatin tri-weekly with a weekly regimen is needed to
establish the long term clinical outcome.
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